#Canada #Toronto #financing #medical cannabis #IM Cannabis

IM Cannabis: Driven by Innovation in Medical Cannabis

The journey of IM Cannabis Corp. (IMC), a leading player in the medical cannabis sector, continues to gain momentum as the company recently announced a successful financing round. On August 7, 2026, IMC confirmed the closing of a notable $250,000 convertible note financing in a private placement with a prominent institutional investor. This move comes as part and parcel of IMC’s strategic expansion into innovative and technology-driven markets, highlighting its commitment to growth and development in the medical cannabis space.

Capital Generation Through Convertible Notes

Under the terms of the financing agreement, dubbed the August Note Purchase Agreement, IMC issued a convertible note with a principal amount of $250,000. The financing was structured with an original issuance discount of 10%, making it an attractive investment for the lender. The convertible note carries an interest rate of 8% per annum, which unfortunately escalates to 14% upon default, clearly marking the risks involved.

What sets convertible notes apart is their flexibility, both for the investors and the issuing company. In this case, IMC is not obliged to repay the note in cash; instead, it plans to meet its obligations through the issuance of common shares upon conversion of the note.

Key Features of the Financing

The conversion terms are designed to benefit both parties. The conversion price is set at the lower of a fixed price of $0.122 per common share or 90% of the lowest daily volume-weighted average price over the previous 20 trading days, offering a potential upside for the investor. There’s also a safeguard in place, ensuring that the conversion price will not dip below $0.02436. Furthermore, the deal includes a 4.99% beneficial ownership cap, which maintains a degree of control over the ownership structure.

In conjunction with the note, IMC issued warrants allowing the purchase of up to 2,052,545 common shares, with an exercise price of C$0.17. These warrants are immediately exercisable and will remain valid for five years, adding another layer of potential return for the investor.

Utilizing Proceeds for Growth

The net proceeds from this financing are earmarked for general corporate purposes, supporting IMC’s ongoing business operations and possibly paving the way for further investments in technology and infrastructure. This funding round underscores IMC’s strategic vision of transforming the cannabis industry through innovative solutions and expansion into new markets.

Commitment to Regulatory Compliance

IMC is committed to regulatory compliance and is taking necessary steps to reserve sufficient common shares for the issuance upon conversion and warrant exercise. It is also in the process of preparing a resale registration statement to comply with the U.S. Securities and Exchange Commission (SEC) requirements—a proactive approach to ensure transparency and build investor confidence.

A Bright Future for IM Cannabis

With operations spanning Israel and Germany, IM Cannabis stands as a beacon of innovation in the medical cannabis sector. The company is leveraging its extensive experience and insights into patient needs to enhance its service offerings continually. As the regulatory landscape evolves, IMC is poised to explore new opportunities, reinforcing its position within the rapidly growing global cannabis market.

As IM Cannabis continues to expand its horizons and operations, it remains to be seen how these strategic financial moves will impact its growth trajectory and contribute to the broader cannabis industry's maturation.